Core Viewpoint - HeartLink Medical-B (02160) has seen a significant increase of over 7%, currently trading at 1.45 HKD with a transaction volume of 19.13 million HKD, following the announcement of a potential restructuring with the group's CRM business to enhance competitiveness and resource integration [1]. Group 1: Company Developments - On July 17, MicroPort Medical and HeartLink Medical announced plans to restructure HeartLink Medical with the group's CRM business to improve internal resource integration and collaboration [1]. - The CRM business, in which the group holds a 50.13% stake, focuses on products for diagnosing, treating, and managing arrhythmias and heart failure, including pacemakers, defibrillators, and cardiac resynchronization therapy devices [1]. - In 2018, MicroPort Medical acquired LivaNova's arrhythmia management business for 190 million USD, which generated 250 million USD in revenue in 2016, while the projected revenue for MicroPort's arrhythmia management in 2024 is 220 million USD, with a loss of 88.05 million USD [1]. Group 2: Market Impact - The integration of HeartLink Medical is expected to create a platform company covering structural heart disease and arrhythmia management, leveraging shared international sales channels to generate synergies between the two business areas [1]. - This restructuring aims to establish a stronger sales network and market influence globally, enhancing the competitive position of the combined entity [1].
港股异动 | 心通医疗-B(02160)再涨超7% 公司有望并购重组微创心律管理业务 进一步增厚产品管线布局